**Appendix Table C48. Time to event outcomes: Comparator, neuroblastoma**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study (Investigator, country, year)** | **Record Number** | **Group (N)** | **Outcome** | **3 yr** | **5 yr** | **Test** | **p** | **HR (95%) CI** | **Outcome\_2** | **3 yr\_2** | **5 yr\_2** | **Test\_2** | **p\_2** | **HR (95% CI)\_2** |
| Berthold, Germany, 2005 | 6760 | 149 | death from any cause or until last exam if patient survived | 62 (54-70) |  | Kaplan-Meier (log-rank) | 0.09 | 1.329 (0.958-1.843) | EFS; time until disease progression or relapse, a 2nd neoplastic disease, or death from any cause or until last exam | 47 (38-55) |  | Kaplan-Meier (log-rank) | 0.02 | 1.404 (1.048-1.881) |
| Kim, South Korea, 2007 | 2870 | 14 | OS | 55.1% (+/- 13.9) |  | Kaplan-Meier |  |  | DFS | 40.6% (+/- 14.7) |  | Kaplan-Meier |  |  |
| Ladenstein, EGBMT, 2008 | 1610 | 2895 | OS |  | 38 (1) |  |  |  | EFS |  | 33 (1) |  |  |  |
| Matthay, US, 2009; 1999 | 6210 | 189 | definition not mentioned |  | 39 (4%) | log-rank | 0.39 (compared to controls) |  | EFS |  | 30 (4) | log-rank | 0.04 (compared to controls) |  |
| Pritchard, United Kingdom, 2005 | 8030 | 32 | time to death from any cause |  | 47 (30-64) | log rank | 0.1 |  | EFS |  | 38 (21-54) | log-rank | 0.08 |  |